Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cholecalciferol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CDC25A | P30304 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholecalciferol SCHEMBL579140 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL12358252 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL7151131 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL15694 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL3127 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL23878716 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL8030832 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL21264875 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL20511118 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL267918 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135029-A1 | COMPOSITIONS AND METHODS FOR INCREASING DIGESTIBILITY OF CALCIUM AND PHOSPHOROUS IN PIGS | PREMEX INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20220291237-A1 | Gene Expression Inflammatory Age and Its Uses | Edifice Health, Inc. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20210206739-A1 | Vitamin Cationic Lipids | TRANSLATE BIO, INC. | 2021-07-08 | — | — | US | disclosed |
| US-20120172336-A2 | Fosfluconazole Derivatives, Synthesis, and Use in Long Acting Formulations | SEPS PHARMA N.V. (BE) | 2012-07-05 | — | — | US | disclosed |
| US-20120172336-A2 | Fosfluconazole Derivatives, Synthesis, and Use in Long Acting Formulations | SEPS PHARMA N.V. (BE) | 2012-07-05 | — | — | US | disclosed |
| US-20120010173-A1 | Fosfluconazole Derivatives, Synthesis, and Use in Long Acting Formulations | SEPS PHARMA N.V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010173-A1 | Fosfluconazole Derivatives, Synthesis, and Use in Long Acting Formulations | SEPS PHARMA N.V. (BE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172336-A2 | Fosfluconazole Derivatives, Synthesis, and Use in Long Acting Formulations | CYP2F1, CYP51A1, CYP3A5 | VDR 1222/4885MEN1 198/4885KMT2A 2789/4885 |
| US-20210206739-A1 | Vitamin Cationic Lipids | APMAP, TTPA, CLN6 | VDR 13/4885MEN1 2292/4885KMT2A 4243/4885 |
| US-20120010173-A1 | Fosfluconazole Derivatives, Synthesis, and Use in Long Acting Formulations | CYP2F1, CYP3A5, CYP51A1 | VDR 737/4885MEN1 263/4885KMT2A 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.